Multiple Sklerose (MS) ist eine chronische neuro-degenerative Erkrankung des zentralen Nervensystems, die durch auto-immun-bedingte Prozesse charakterisiert ist. T Zellen wurden als wesentliche pro-inflammatorische Mediatoren mit der Pathogenese der MS assoziiert. In gesunden Individuen passen Immunzellen ihren Metabolismus, wie die mitochondriale Atmung und Glykolyse, ihrer jeweiligen Funktion und ihrem inflammatorischen Phänotyp an. Im Krankheitsverlauf der MS ist die Bedeutung der metabolischen Anpassung und der damit verbundenen pro-inflammatorischen Mechanismen von T Zell-Subpopulationen noch nicht eindringlich erforscht. Um dieser Fragestellung nachzugehen wurden Relapsing Remitting MS (schubförmig, RRMS) Patienten und sorgfältig aufeinander abgestimmte gesunde Kontrollprobanden als Teil der Studie Depression und Immunfuktion bei MS rekrutiert (n=62). Den Patienten und gesunden Kontrollprobanden wurde Nüchternblut entnommen, woraus periphäre mononukleäre Blutzellen (PBMC) aufgearbeitet wurden, um anschließend CD4+ und CD8+ T Zellen zu isolieren. Die erzielten Ergebnisse zeigten CD4+ T Zell-spezifische Verringerungen der mitochondrialen Atmung und glykolytischen Aktivität in der MS Patienten Kohorte im Vergleich zur Kohorte der gesunden Kontrollprobanden. Darüberhinaus wurden, zusätzlich zu den umfangreichen phänotypischen Charakterisierungen der PBMCs via Durchflußzytometrie, erhöhte Werte des mitochondrialen Membranproteins CPT1a in CD4+ T Zell-Subpopulationen in der MS Patienten Kohorte detektiert. Die Analyse der CD4+ CD25- CD127+ konventionellen T Zell- Subpopulation ergab leicht erniedrigte Werte von IL7-Rα in MS Patienten. Genexpressionsanalysen, die mit pro-inflammatorischen und metabolischen Genen assoziiert sind, ergaben keine Veränderungen in den T Zell-Subpopulationen der MS Patienten. Die in dieser Studie erzielten Ergebnisse weisen auf Funktionsstörungen bei der metabolischen Anpassung in T-Zell-Subpopulationen bei MS Patienten hin und helfen, den Beitrag des Immunmetabolismus bei der Pathogenese der MS Erkrankung besser zu verstehen. / Multiple Sclerosis (MS) is a chronic neurodegenerative disease of the central nervous system characterized by autoimmune-mediated mechanisms. T cells have been associated as central pro-inflammatory mediators in MS pathogenesis. In healthy individuals, immune cells adapt metabolic programs like mitochondrial respiration and glycolysis based on their function and inflammatory phenotype. However, the relevance of metabolic reprogramming and associated pro-inflammatory mechanisms in T cell subpopulations in MS disease is not well understood yet. To address this question, Relapsing Remitting MS (RRMS) patients and meticulously matched healthy control (HC) participants were recruited as part of the clinical study Depression and Immune Function in MS (n=62). Blood samples, after a period of fasting, were collected and CD4+ and CD8+ T cells isolated from peripheral blood mononuclear cells (PBMC). The results obtained demonstrated decreased mitochondrial and glycolytic activity specific to CD4+ T cells in the MS patient cohort compared to the HC participant cohort. Furthermore, increased CPT1a mitochondrial membrane protein levels were detected in CD4+ T cell subpopulations in the MS patient cohort as assessed in comprehensive flow cytometry PBMC phenotype investigations. The analysis of the CD4+ CD25- CD127+ conventional T cell subpopulation moreover revealed a trend of decreased IL7-Rα expression levels in MS patients. Gene expression measurements of pro-inflammatory and metabolic genes did not reveal alterations in MS patients’ T cell subpopulations. The results obtained in this study allude to dysfunctions in metabolic reprogramming in T cell subpopulations in MS patients and help to better understand the contribution of immunometabolism in the pathogenesis of MS disease.

Objectives: The management of patients with multifocal motor neuropathy (MMN) under everyday clinical conditions has been insufficiently studied. We therefore collected comprehensive observational data on patients with MMN who received intravenous (IV) or subcutaneous (SC) immunoglobulins (IGs) as maintenance therapy. Methods: This was a prospective, noninterventional study (registry) in neurological centres (hospitals and offices) throughout Germany. Results: As of 1 December 2015, 80 patients with MMN were included (mean age 55.4 ± 9.8 years, 67% males, mean disease duration 10.7 ± 10.2 years). The affected limb regions were predominantly distal muscle groups of the upper extremities. On the inflammatory neuropathy cause and treatment (INCAT) scale, 94% of the patients had some disability in the arms and 61% in the legs. At inclusion, 98.8% received IVIG and 1.3% SCIG. Substantial variation was observed between IVIG treatment intervals (every 0.7 to 17.3 weeks) and dosage (0.2–2.1 g/kg body weight received during a single administration; mean monthly dosage, 0.9 g/kg body weight). However, the mean monthly dosage was steady over time. At 1-year follow up, improvement was seen in muscle strength, INCAT and quality of life (QoL) scores (SF-36 questionnaire). Conclusions: The management of patients with MMN in everyday clinical practice demonstrates a wide range of absolute dosages and treatment intervals of IG, supporting the recommended practice of determining treatment dose on an individual patient basis. The improvements in muscle strength and reduction in disability, accompanied by increased QoL, strengthen the case for use of IG as a maintenance treatment for MMN.

Angeborene lymphoide Zellen (ILCs) sind sich im Gewebe befindliche Zellen, die eine wichtige Rolle bei der Aufrechterhaltung der Gewebehomöostase spielen. ILCs wurden in verschiedenen Organen untersucht. Ob ILCs im zentralen Nervensystem (ZNS) vorhanden sind und wenn ja, welchen ​​Phänotyp und welche funktionellen Eigenschaften sie in diesem Organ aufweisen, sind Fragen, die bisher unbeantwortet blieben. NK-Zellen sind die seit langem bekannten ILC-Mitglieder, die viele Merkmale mit ILC1s teilen. Im Zusammenhang mit der Autoimmunität wurde gezeigt, dass NK-Zellen eine immunmodulatorische Rollen spielen. Anhand des Tiermodells von Multiple Sklerose, der experimentellen autoimmunen Enzephalomyelitis, zeigte unsere Gruppe, dass reife NK-Zellen auf CX3CR1-abhängige Weise in das ZNS rekrutiert werden. Auf der Grundlage dieser Beobachtungen will ich in meinem PhD Projekt die Chemokinrezeptoren definieren, die die Rekrutierung der unreifen NK-Zellen in das entzündete ZNS vermitteln. Des Weiteren will ich herausfinden, ob die phänotypisch definierten NK-Zellen (CD3-NK1.1 + -Zellen) die im gesunden ZNS vorhanden sind, echte NK-Zellen sind, oder sie zu den ILC1s gezählt werden können. Die Ergebnisse der vorliegenden Arbeit zeigen, dass die im gesunden ZNS vorhandenen CD3-NK1.1+ -Zellen verschiedene Typ-1-ILC-Subsets umfassen: NK-Zellen, ILC1s, Intermediat-ILC1s und Ex-ILC3s. CXCR3 wurde auf ILC1s und einer Fraktion von unreifen NK-Zellen exprimiert, trug jedoch nicht zur Rekrutierung von NK-Zellen in das ZNS im EAE-Modell bei. Die Expression von CD49a, CD69, CXCR6, DNAM-1high, TRAIL und CD200R und das Fehlen von Eomes unterschieden die ILC1 von den NK-Zellen im ZNS. Zusätzlich ILC1s sezernierten mehr TNF-α als NK-Zellen. ILC1s waren die dominante Typ-1-ILC Subgruppe im Plexus choroideus und im Gehirnparenchym und waren auch in den Meningen vorhanden. Zusammenfassend bietet die vorliegende Arbeit zum ersten Mal eine umfassende Charakterisierung von ILCs des Typs I im ZNS. / Innate lymphoid cells (ILCs) are tissue resident cells that play important roles in the maintenance of tissue homeostasis. ILCs have been characterized in diverse organs like the gut and liver. However, whether ILCs are present in the central nervous system (CNS) and if so, what are their phenotype and function in this organ are questions that remain unanswered. NK cells are the longer-known ILC members that share many phenotypical and functional features with ILC1s. Using the animal model of MS, the experimental autoimmune encephalomyelitis (EAE), our group showed that protective mature NK cells are recruited to the CNS on an CX3CR1-dependent manner. Based on that observations, my PhD project aimed to 1) define the chemokine receptors that mediate the recruitment of the immature NK cells into the inflamed CNS and to 2) determine whether the phenotypically defined NK cells (CD3-NK1.1+ cells) that are present in the CNS during steady state constitute bona fide NK cells or constitute also other group 1 ILC subsets. The results of this work indicate that the CD3-NK1.1+ cells present in the healthy CNS comprise diverse group 1 ILC subsets that include conventional NK cells, ILC1s, intermediate-ILC1s and ex-ILC3s. CXCR3 was expressed on ILC1s and a fraction of immature NK cells, but did not contributed to the recruitment of NK cells into the CNS in the EAE model. In addition, the phenotypic and functional characterization of the newly identified CNS-ILC1s is described. The exclusive expression of CD49a, CD69, CXCR6, DNAM-1high, TRAIL and CD200R, and lack of Eomes distinguished the ILC1s from the NK cells in the CNS. IILC1s secreted IFN-γ and more TNF-α than NK cells upon stimulation in the healthy and EAE mice and were the dominant group 1 ILC subset in the choroid plexus and brain parenchyma and were also present in the meninges. In sum, the present work provides for the first time a comprehensive characterization of group 1 ILCs in the CNS.

No description available.

La barrière hémato-encéphalique (BHE) protège le système nerveux central (SNC) en contrôlant le passage des substances sanguines et des cellules immunitaires. La BHE est formée de cellules endothéliales liées ensemble par des jonctions serrées et ses fonctions sont maintenues par des astrocytes, celles ci sécrétant un nombre de facteurs essentiels. Une analyse protéomique de radeaux lipidiques de cellules endothéliales de la BHE humaine a identifié la présence de la voie de signalisation Hedgehog (Hh), une voie souvent liées à des processus de développement embryologique ainsi qu’au niveau des tissus adultes. Suite à nos expériences, j’ai déterminé que les astrocytes produisent et secrètent le ligand Sonic Hh (Shh) et que les cellules endothéliales humaines en cultures primaires expriment le récepteur Patched (Ptch)-1, le co-récepteur Smoothened (Smo) et le facteur de transcription Gli-1. De plus, l’activation de la voie Hh augmente l’étanchéité des cellules endothéliales de la BHE in vitro. Le blocage de l’activation de la voie Hh en utilisant l’antagoniste cyclopamine ainsi qu’en utilisant des souris Shh déficientes (-/-) diminue l’expression des protéines de jonctions serrées, claudin-5, occcludin, et ZO-1. La voie de signalisation s’est aussi montrée comme étant immunomodulatoire, puisque l’activation de la voie dans les cellules endothéliales de la BHE diminue l’expression de surface des molécules d’adhésion ICAM-1 et VCAM-1, ainsi que la sécrétion des chimiokines pro-inflammatoires IL-8/CXCL8 et MCP-1/CCL2, créant une diminution de la migration des lymphocytes CD4+ à travers une monocouche de cellules endothéliales de la BHE. Des traitements avec des cytokines pro-inflammatoires TNF-α and IFN-γ in vitro, augmente la production de Shh par les astrocytes ainsi que l’expression de surface de Ptch-1 et de Smo. Dans des lésions actives de la sclérose en plaques (SEP), où la BHE est plus perméable, les astrocytes hypertrophiques augmentent leur expression de Shh. Par contre, les cellules endothéliales de la BHE n’augmentent pas leur expression de Ptch-1 ou Smo, suggérant une dysfonction dans la voie de signalisation Hh. Ces résultats montrent que la voie de signalisation Hh promeut les propriétés de la BHE, et qu’un environnement d’inflammation pourrait potentiellement dérégler la BHE en affectant la voie de signalisation Hh des cellules endothéliales. / The blood-brain barrier (BBB), composed of tightly bound endothelial cells (ECs), regulates the entry of blood-borne molecules and immune cells into the CNS. Recent studies indicate that the Hedgehog (Hh) signaling pathway in adult tissues plays an important role in vascular proliferation, differentiation and tissue repair. Using a lipid membrane raft-based proteomic approach, I have identified the Hedgehog (Hh) pathway as a signaling cascade involved in preserving and upkeeping BBB functions. My study shows that human astrocytes express and secrete Sonic Hh (Shh) and conversely, that human BBB-ECs bear the Hh receptor Patched-1 (Ptch-1), the signal transducer Smoothened (Smo) as well as transcription factors of the Gli family. Furthermore, activation of the Hh pathway in BBB-ECs restricts the passage of soluble tracers in vitro. By blocking the Hh signaling in vitro and by using Shh knock-out (-/-) embryonic mice, I demonstrate a reduced expression of TJ molecules claudin-5, occludin and ZO-1. Hh activation also decreases the surface expression of cell adhesion molecules ICAM-1 and VCAM-1, and decreases BBB-ECs secretion of pro-inflammatory chemokines IL-8/CXCL8 and monocytes chemoattractant protein 1 MCP-1/CCL2, resulting in a reduction of migrating CD4+ lymphocytes across human BBB-EC monolayers. In vitro treatment with inflammatory cytokines TNF-α and IFN-γ, upregulates the production of astrocytic Shh and the BBB-EC surface expression of Ptch-1 and Smo. In active Multiple Sclerosis (MS) lesions, in which the BBB is disrupted, Shh expression is drastically upregulated in hypertrophic astrocytes, while Ptch-1 and Smo expression is down-regulated or left unchanged, suggesting that a deregulation in the Hh signaling pathway may prevent the barrier stabilizing properties of Hh. Our data demonstrate an anti-inflammatory and BBB-promoting effect of astrocyte-secreted Hh and suggest that a pro-inflammatory environment disrupt the BBB by impacting, at least in part, on Hh signaling in brain ECs.

La barrière hémato-encéphalique (BHE) protège le système nerveux central (SNC) en contrôlant le passage des substances sanguines et des cellules immunitaires. La BHE est formée de cellules endothéliales liées ensemble par des jonctions serrées et ses fonctions sont maintenues par des astrocytes, celles ci sécrétant un nombre de facteurs essentiels. Une analyse protéomique de radeaux lipidiques de cellules endothéliales de la BHE humaine a identifié la présence de la voie de signalisation Hedgehog (Hh), une voie souvent liées à des processus de développement embryologique ainsi qu’au niveau des tissus adultes. Suite à nos expériences, j’ai déterminé que les astrocytes produisent et secrètent le ligand Sonic Hh (Shh) et que les cellules endothéliales humaines en cultures primaires expriment le récepteur Patched (Ptch)-1, le co-récepteur Smoothened (Smo) et le facteur de transcription Gli-1. De plus, l’activation de la voie Hh augmente l’étanchéité des cellules endothéliales de la BHE in vitro. Le blocage de l’activation de la voie Hh en utilisant l’antagoniste cyclopamine ainsi qu’en utilisant des souris Shh déficientes (-/-) diminue l’expression des protéines de jonctions serrées, claudin-5, occcludin, et ZO-1. La voie de signalisation s’est aussi montrée comme étant immunomodulatoire, puisque l’activation de la voie dans les cellules endothéliales de la BHE diminue l’expression de surface des molécules d’adhésion ICAM-1 et VCAM-1, ainsi que la sécrétion des chimiokines pro-inflammatoires IL-8/CXCL8 et MCP-1/CCL2, créant une diminution de la migration des lymphocytes CD4+ à travers une monocouche de cellules endothéliales de la BHE. Des traitements avec des cytokines pro-inflammatoires TNF-α and IFN-γ in vitro, augmente la production de Shh par les astrocytes ainsi que l’expression de surface de Ptch-1 et de Smo. Dans des lésions actives de la sclérose en plaques (SEP), où la BHE est plus perméable, les astrocytes hypertrophiques augmentent leur expression de Shh. Par contre, les cellules endothéliales de la BHE n’augmentent pas leur expression de Ptch-1 ou Smo, suggérant une dysfonction dans la voie de signalisation Hh. Ces résultats montrent que la voie de signalisation Hh promeut les propriétés de la BHE, et qu’un environnement d’inflammation pourrait potentiellement dérégler la BHE en affectant la voie de signalisation Hh des cellules endothéliales. / The blood-brain barrier (BBB), composed of tightly bound endothelial cells (ECs), regulates the entry of blood-borne molecules and immune cells into the CNS. Recent studies indicate that the Hedgehog (Hh) signaling pathway in adult tissues plays an important role in vascular proliferation, differentiation and tissue repair. Using a lipid membrane raft-based proteomic approach, I have identified the Hedgehog (Hh) pathway as a signaling cascade involved in preserving and upkeeping BBB functions. My study shows that human astrocytes express and secrete Sonic Hh (Shh) and conversely, that human BBB-ECs bear the Hh receptor Patched-1 (Ptch-1), the signal transducer Smoothened (Smo) as well as transcription factors of the Gli family. Furthermore, activation of the Hh pathway in BBB-ECs restricts the passage of soluble tracers in vitro. By blocking the Hh signaling in vitro and by using Shh knock-out (-/-) embryonic mice, I demonstrate a reduced expression of TJ molecules claudin-5, occludin and ZO-1. Hh activation also decreases the surface expression of cell adhesion molecules ICAM-1 and VCAM-1, and decreases BBB-ECs secretion of pro-inflammatory chemokines IL-8/CXCL8 and monocytes chemoattractant protein 1 MCP-1/CCL2, resulting in a reduction of migrating CD4+ lymphocytes across human BBB-EC monolayers. In vitro treatment with inflammatory cytokines TNF-α and IFN-γ, upregulates the production of astrocytic Shh and the BBB-EC surface expression of Ptch-1 and Smo. In active Multiple Sclerosis (MS) lesions, in which the BBB is disrupted, Shh expression is drastically upregulated in hypertrophic astrocytes, while Ptch-1 and Smo expression is down-regulated or left unchanged, suggesting that a deregulation in the Hh signaling pathway may prevent the barrier stabilizing properties of Hh. Our data demonstrate an anti-inflammatory and BBB-promoting effect of astrocyte-secreted Hh and suggest that a pro-inflammatory environment disrupt the BBB by impacting, at least in part, on Hh signaling in brain ECs.

<p>Microglia are a population of specialized, tissue-resident immune cells that make up around 10% of total cells in our brain. They actively prune neuronal synapses, engulf cellular debris, and misfolded protein aggregates such as the Alzheimer’s Disease (AD)-associated amyloid-beta (Aβ) by the process of phagocytosis. During AD, microglia are unable to phagocytose Aβ, perhaps due to the several disease-associated changes affecting their normal function. Functional molecules such as lipids and metabolites also influence microglial behavior but have primarily remained uncharacterized to date. The overarching question of this work is, <i>How do microglia become dysfunctional in chronic inflammation</i>? To this end, we developed new chemical tools to better understand and investigate the microglial response to Aβ <i>in vitro</i> and <i>in vivo</i>. Specifically, we introduce three new tools. (1) Recombinant human Aβ was developed via a rapid, refined, and robust method for expressing, purifying, and characterizing the protein. (2) A pH-sensitive fluorophore conjugate of Aβ (called Aβ^pH) was developed to identify and separate Aβ-specific phagocytic and non-phagocytic glial cells <i>ex vivo</i> and <i>in vivo</i>. (3) New lysosomal, mitochondrial, and nuclei-targeting pH-activable fluorescent probes (called LysoShine, MitoShine, and NucShine, respectively) to visualize subcellular organelles in live microglia. Next, we asked, <i>What changes occur to the global lipid and metabolite profiles of microglia in the presence of Aβ in vitro and in vivo</i>? We screened 1500 lipids comprising 10 lipid classes and 700 metabolites in microglia exposed to Aβ. We found significant changes in specific lipid classes with acute and prolonged Aβ exposure. We also identified a lipid-related protein that was differentially regulated due to Aβ <i>in vivo</i>. This new lipid reprogramming mechanism “turned on” in the presence of cellular stress was also present in microglia in the brains of the 5xFAD mouse model, suggesting a generic response to inflammation and toxicity. It is well known that activated microglia induce reactive astrocytes during inflammation. Therefore, we asked, <i>What changes in proteins, lipids, and metabolites occur in astrocytes due to their reactive state? </i>We provide a comprehensive characterization of reactive astrocytes comprising 3660 proteins, 1500 lipids, and 700 metabolites. These microglia and astrocytes datasets will be available to the scientific community as a web application. We propose a final model wherein the molecules secreted by reactive astrocytes may also induce lipid-related changes to the microglial cell state in inflammation. In conclusion, this thesis highlights chemical neuroimmunology as the new frontier of neuroscience propelled by the development of new chemical tools and techniques to characterize glial cell states and function in neurodegeneration.</p>

Die Autoimmunenzephalitis ist eine kürzlich beschriebene entzündliche Erkrankung des zentralen Nervensystems, die Gedächtnisdefizite, Psychosen, oder epileptische Anfälle hervorrufen kann. Derzeit ist hingegen noch nicht ausreichend verstanden, welche pathologischen Veränderungen zu den kognitiven Defiziten führen und welche neuropsychologischen und bildgebenden Langzeitoutcomes zu erwarten sind. Anhand von strukturellen und funktionellen Bildgebungsanalysen zeigt diese Dissertation, dass kognitive Defizite auch nach der akuten Phase der Autoimmunenzephalitis fortbestehen können. Bei der LGI1-Enzephalitis gehen Gedächtnisdefizite mit fokalen strukturellen Läsionen im Hippocampus einher. Durch eine funktionelle Störung der Resting-State-Konnektivität des Default-Mode- und Salienznetzwerkes beeinträchtigen diese Hippocampusläsionen auch Hirnregionen außerhalb des limbischen Systems. Bei Patient:innen mit NMDA-Rezeptor-Enzephalitis finden sich in der longitudinalen neuropsychologischen Untersuchung trotz guter allgemeiner Genesung auch noch mehrere Jahre nach der Akutphase persistierende Defizite des Gedächtnisses und exekutiver Funktionen. Zuletzt zeigt eine transdiagnostische Analyse, dass der anteriore Hippocampus eine erhöhte Vulnerabilität gegenüber immunvermittelten pathologischen Prozessen aufweist. Diese Ergebnisse legen nahe, dass kognitive Symptome auch noch nach der Entlassung aus der stationären Behandlung fortbestehen können. Sowohl umschriebene strukturelle Hippocampusläsionen als auch Veränderungen in makroskopischen funktionellen Hirnnetzwerken tragen zur pathophysiologischen Erklärung dieser Symptome bei. Zudem erlauben diese Ergebnisse einen Einblick in neuroplastische Veränderungen des Gehirns und haben weitreichende Implikationen für die Langzeitversorgung und das Design zukünftiger klinischer Studien. / Autoimmune encephalitis is a recently described inflammatory disease of the central nervous system that can cause memory deficits, psychosis, or seizures. The trajectory of cognitive dysfunction and the underlying long-term imaging correlates are, however, not yet fully understood. By using advanced structural and functional neuroimaging, this thesis shows that cognitive deficits persist beyond the acute phase. In LGI1 encephalitis, MRI postprocessing revealed that memory deficits are related to focal structural hippocampal lesions. These hippocampal lesions propagate to brain areas outside the limbic system through aberrant resting-state connectivity of the default mode network (DMN) and the salience network. In NMDA receptor encephalitis, a longitudinal analysis of neuropsychological data describes persistent cognitive deficits, especially in the memory and executive domains, despite good physical recovery several years after the acute disease. Lastly, a transdiagnostic analysis reveals that the anterior hippocampus is particularly vulnerable to immune-mediated damage. In conclusion, these results demonstrate that cognitive symptoms in autoimmune encephalitis can persist beyond discharge from neurological care. Both discrete structural hippocampal damage and changes in macroscopic functional networks shed light on the pathophysiological basis of these symptoms. These findings help to explain how the brain responds to pathological damage and have substantial implications for long-term patient care and the design of future clinical studies.